Sentences with phrase «federal aids program»

Please note that Federal aids program deadline may be different from the state aids deadlines.

Once you have a criminal record it is difficult to find a job, to find a landlord comfortable renting to you or even to participate in some state and federal aid programs.

Sprague Brook Park was acquired by using state and federal aid programs to assume title to more than 2,200 acres of parkland (including Eighteen Mile Creek, Beeman's Creek and Larkin Woods) in May 1963.

Konopko went on to explain additional federal aid programs which can be used by affected homeowners on River, Beach, and Grassy Point Roads.

Policymakers should encourage (or push) districts to create similar options for their students by tying Title I and other federal aid programs to initiatives that promote online learning for the most talented students and that also provide physical locations for these students to do their advanced group work.

Proposals to move to one grant and one loan have the potential to attract bipartisan support, especially if funds from eliminated programs are kept within the federal aid programs rather than used for other purposes such as deficit reduction.

This quadrennial dataset includes student - level records for approximately 100,000 undergraduates and is designed to be nationally representative of students attending institutions eligible for federal aid programs.

Melinda Young currently serves as the district's federal and state program coordinator, where she oversees, among other things, the Title One federal aid program.

As part of a legal change, the United States House of Representatives Committee on Education decided on a 90 - 10 rule that would allow for - profit educators to accept money from federal aid programs so long as 10 % of their students paid out of pocket.

Professional Judgment (PJ) For need - based federal aid programs, the financial aid administrator can adjust the EFC, adjust the COA, or change the dependency status (with documentation) when extenuating circumstances exist.

The future of the Stafford loan program is uncertain (as is just about any federal aid program for higher education) but it does appear that Congress is looking at a proposal to change the Stafford Loan interest rates from a fixed rate to a variable rate and making 6.8 % the maximum percentage rate that will be allowed to be imposed on borrowers.

This guide provides definitive information about federal aid programs, including the Pell Grants, Federal Direct Loans, Federal Family Education Loans (FFEL), Federal Supplemental Educational Opportunity Grants (FSEOG), Federal Work - Study (FWS) and Federal Perkins Loans.

Other federal aid programs, like Pell Grants and Federal Direct Loans, should continue with minimal impact, as these are part of permanent and multi-year funding.

Each school that participates in the federal aid programs is required to post a net price calculator on its web site.

But regardless of whether a student graduates or drops out, the school's revenue from federal aid programs does not vary.

But that does not absolve the federal government from ensuring that federal aid programs, especially options for defaulted borrowers, serve in the interest of helping students find success in repayment.

Many homeowners believe that federal aid programs will cover the cost of rebuilding if they are hit by a flood.

Not exact matches

The February federal budget deal, meanwhile, hikes outlays in both of the two categories of «discretionary» spending, defense and federal programs from foreign aid to housing subsidies, by an unprecedented 12 %, or $ 150 billion a year in 2018 and 2019.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Generally, if you see a loan type with «Direct» in the name on «My Federal Student Aid,» then it is a Direct Loan; otherwise, it is a loan made under another federal student loan pFederal Student Aid,» then it is a Direct Loan; otherwise, it is a loan made under another federal student loan pfederal student loan program.

For four decades it has been much debated, since the aid program — currently capped at around $ 4 billion — accounts for a significant amount of the federal government's discretionary spending.

-- Member of Parliament David Yurdiga «The federal government thinks that it is acceptable to run a $ 30 billion deficit and spending billions on foreign aid and international climate change projects, as well as on newcomer settlement programs all the while cutting over $ 100 million from the three northern territories over the course of the next five years.

Pell Grants are a type of federal student aid, typically awarded to students enrolled in an undergraduate program, although some exceptions may apply.

Wyoming Catholic College has decided to opt out of Title IV — specifically, federal student aid and loan programs.

He heard government leaders talk about balancing the budget by cutting back on the food stamp program, even while they rescued a struggling aircraft corporation with massive federal aid.

But the federal agriculture minister David Littleproud has hit back, saying the aid program has mutual benefits for Australian cattle producers who rely on a healthy, sustainable live trade to Vietnam.

Fifty - seven players were implicated in a financial - aid scandal that the feds call «perhaps the largest centralized fraud upon the federal Pell Grant program ever committed.»

Additional Content Requirements: None Guidance Materials: Rhode Islands» Coordinated School Health Program, THRIVE, has produced a comprehensive District Health & Wellness Subcommittee Toolkit to aid subcommittees in creating and implementing wellness policies as required by state and federal law.

A northwest suburban high school district is looking to quit the National School Lunch Program, giving up about $ 900,000 in federal aid before strict new guidelines would restrict some fundraisers such as school bake sales.

They also note that a state system for automatically enrolling federal aid recipients in the free lunch program, a process called direct certification, has not been perfected.

Federal aid under the Special Supplemental Food Program for Women, Infants and Children (WIC), provides formula but no special supplements to those who nurse.

Christian's project contributes about $ 250,000 toward the cost of the program and receives about $ 1 in federal school aid through the Chicago Public Schools for each meal served, according to Maureen George, the project's program director.

Federal programs that aid Upstate New York will be preserved as part of a bipartisan deal in Congress for a $ 1 trillion spending bill, U.S. Senate Minority Leader Chuck Schumer said.

Legislation Rep. Elise Stefanik introduced May 17 to extend the federal Perkins Loan college financial aid program for two years gained momentum as the House returned from recess on Tuesday, picking up a dozen new co-sponsors.

Rep. Peter King, other New York members of Congress and comedian Jon Stewart denounced as «downright irresponsible» a Trump administration proposal that would change the leadership of a federal health program that provides aid to 9/11 first responders.

Syracuse will receive a boost of almost 15 percent in federal aid for affordable housing and community development after Congress spared programs Trump wanted to eliminate in this year's budget.

Allred called on Attorney General Eric Schneiderman to investigate whether Syracuse was in compliance with a federal law that requires colleges and universities that participate in federal financial aid programs to disclose information about crime on campus.

It would end $ 2.3 billion of annual federal aid to counties to pay for Medicaid, and instead require that the state of New York fund the programs instead.

The Cuomo administration says the program actually saves money for the state by leveraging federal aid for certain noncitizens whose care is now fully paid for with state dollars.

The program would cover tuition costs that remain once other state and federal aid is applied, at an estimated cost of about $ 163 million per year, Cuomo's office said.

And the federal government almost entirely finances the Department of Health and Mental Hygiene's HIV / AIDS Prevention and Treatment program.

SUNY Chancellor Nancy Zimpher said cuts to programs that help disadvantaged high school students gain the opportunity to attend college, as well as reductions to federal college aid and cuts to medical research, including cancer research, would have a huge negative impact on New York's colleges.

Other projects aided by the federal program include: Seneca Exchange Larkin Partners for a mixed - use development on Seneca Street; Multisorb Technologies for expansion of its West Seneca and Cheektowaga plants; and Iskalo Development's conversion of the former Kane - Doyle auto dealership in Kenmore into a multi-tenant office and retail complex.

«They tend to be relatively cost - effective for sponsoring governments because each of the programs use a «last - dollar» model whereby the state subsidizes tuition costs after the student has exhausted all other available state and federal financial aid.»

AHCA does reduce federal aid for Medicaid, but it leaves eligibility standards alone — meaning no one covered by the program (more than 6 million, or one in three New Yorkers) would necessarily be displaced.

Legislation U.S. Rep. Elise Stefanik, R - Willsboro, introduced May 17 to extend the federal Perkins Loan college financial aid program for two years gained momentum as the House returned from recess on Tuesday, picking up a dozen new co-sponsors, according to the Library of Congress government information web site.

At the same time, Cuomo proposed a student - loan relief package that would be aimed at aiding SUNY and CUNY graduates who participate in a federal program.

Cuomo's program would meet the difference for students who are already getting federal and state aid but still can not fully meet their tuition obligations.

But the governor also said that the state could use the two - month delay to get a better sense of what could be coming from the federal government as President Donald Trump and the Republican Congress craft their own budget, which is anticipated to result in less aid for New York state — especially in terms of support for its sprawling Medicaid program.

On July 17, 2013, in response to the impact of these floods and the lack of approved federal disaster aid for individual assistance, the Governor announced the creation of the Mohawk Valley and 2013 Upstate Flood Recovery Program.